A Phase 3 interventional study of BI 10773 and BI 10773 Placebo in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 114 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-04.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.
Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 18th largest by enrollment, is one of 4 that started in 2013, is one of 28 in phase 3, and was the 27th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 30–75
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18–75 · Men only
JW Pharmaceutical · Sites in Korea, Republic of
Ages 19+
Celltrion · Sites in Korea, Republic of
Ages 19+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 30–75
By country, each count listing its studies:
empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 708 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 79 across the 130 interventional studies. Of the 91 that completed or were terminated, 38 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 130 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim: 2 open now, 3 under way, 2 of them phase 3. Of 125 finished, 109 (87%) have results posted.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 25th largest by enrollment of the 96 interventional ones that give a count, is one of 9 that started in 2013, is one of 50 in phase 3, and was the 68th registered.
Boehringer Ingelheim’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
10 of the studies testing empagliflozin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07093476Phase 3CelltrionEfficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin | 2026-12 |
| NCT05164263Getz PharmaReal World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study | 2026-12-31 |
| NCT06989723Seoul National University Bundang HospitalPioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes | 2026-12-31 |
| NCT07442006JW PharmaceuticalGlycemic Variability of Combination Therapies in T2DM | 2027-03-31 |
| NCT05960656The University of Texas Health Science Center at San AntonioSGLTi, Hepatic Glucose Production and Ketogenesis | 2027-06-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Among Boehringer Ingelheim’s 130 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The objective of the study is to investigate the efficacy, safety and tolerability of linagliptin 5 mg qd compared to placebo given for 24 weeks in inadequately controlled T2DM patients on empagliflozin 10 mg or 25 mg and maximum tolerated dose of metformin. The primary objective of efficacy evaluation is planned after 24 weeks of treatment. The study is designed to show superiority of the combination of empagliflozin and linagliptin over empagliflozin alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Empagliflozin open label treatment period
Drug: BI 10773
Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo add on run-in
Drug: BI 10773 / BI 1356 Placebo · Drug: BI 10773
Empagliflozin / Linagliptin 25/5 mg Dose FDC active
Drug: BI 10773 / BI 1356 · Drug: BI 10773 Placebo
Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
Drug: BI 10773 / BI 1356 Placebo · Drug: BI 10773
Empagliflozin / Linagliptin 10/5 mg Dose FDC active
Drug: BI 10773 Placebo · Drug: BI 10773 / BI 1356
Empagliflozin open label treatment period
Drug: BI 10773
Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
Drug: BI 10773 · Drug: BI 10773 / BI 1356 Placebo
Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo add on run-in
Drug: BI 10773 · Drug: BI 10773 / BI 1356 Placebo
Empagliflozin active
Empagliflozin placebo
Drug pages: Empagliflozin · Linagliptin
Empagliflozin / Linagliptin 25/5 mg Dose FDC active
Empagliflozin active
Drug pages: Empagliflozin · Linagliptin
Empagliflozin / Linagliptin 10/5 mg Dose FDC active
Empagliflozin / Linagliptin 10/5 mg Dose placebo FDC
Empagliflozin active
Empagliflozin active
Empagliflozin active
Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
Empagliflozin placebo
Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
Empagliflozin active
Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
Change From Baseline of HbA1c After 24 Weeks of Treatment.
Change from baseline in Glycated haemoglobin (HbA1c) \[%\] after 24 weeks of treatment with double-blind trial medication, i.e. HbA1c change from baseline at Week 24. The term "baseline" was not used to refer to measurements prior to the administration of open-label medication. Such measurements were referred to as "pre-treatment". Analyses of change from pre-treatment used the last value before first administration of open-label medication as point of reference. Observed Case (OC): This method analyse only available data that were observed while patients were on treatment, i.e., excluding the missing data. All values measured after rescue medication taken were set to missing. Full Analysis Set (FAS): Includes all patients in the Treated set who had a baseline HbA1c assessment and at least 1 on-treatment HbA1c assessment during the double-blind part of the trial.
Time frame: Baseline and 24 weeks
Fasting Plasma Glucose (FPG) Change From Baseline at 24 Weeks.
Change from baseline FPG (mmol/L) after 24 weeks of treatment with double-blind trial medication, i.e. FPG change from baseline at Week 24.
Time frame: Baseline and 24 weeks
Subjects randomised to 16 week(wk) open-label (OL) treatment with either empagliflozin (empa) 25 or empa 10 treatment, thereafter subjects entered to 1 wk open label placebo (Plc) add-on period in order to complete further eligibility evaluations before being randomised into 1 of the 24 wk double-blind treatment groups.
| Milestone | Empa 10 mg OL | Empa 25 mg OL | Lina5 (E10) | Plc (E10) | Lina5 (E25) | Plc (E25) |
|---|---|---|---|---|---|---|
| Started | 354 | 355 | 0 | 0 | 0 | 0 |
| Completed | 256 | 226 | 0 | 0 | 0 | 0 |
| Not completed | 98 | 129 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 5 | 15 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 5 | 5 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 4 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 10 | 0 | 0 | 0 | 0 |
| Withdrew: Not treated | 2 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other reason not defined above | 77 | 94 | 0 | 0 | 0 | 0 |
| Milestone | Empa 10 mg OL | Empa 25 mg OL | Lina5 (E10) | Plc (E10) | Lina5 (E25) | Plc (E25) |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 126 | 130 | 114 | 112 |
| Completed | 0 | 0 | 111 | 118 | 102 | 105 |
| Not completed | 0 | 0 | 15 | 12 | 12 | 7 |
| Withdrew: Adverse event | 0 | 0 | 4 | 5 | 3 | 2 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 4 | 1 | 5 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 2 | 0 | 1 |
| Withdrew: Not treated | 0 | 0 | 0 | 2 | 2 | 0 |
| Withdrew: Other reason not defined above | 0 | 0 | 4 | 2 | 2 | 1 |
Change from baseline in Glycated haemoglobin (HbA1c) \[%\] after 24 weeks of treatment with double-blind trial medication, i.e. HbA1c change from baseline at Week 24. The term "baseline" was not used to refer to measurements prior to the administration of open-label medication. Such measurements were referred to as "pre-treatment". Analyses of change from pre-treatment used the last value before first administration of open-label medication as point of reference. Observed Case (OC): This method analyse only available data that were observed while patients were on treatment, i.e., excluding the missing data. All values measured after rescue medication taken were set to missing. Full Analysis Set (FAS): Includes all patients in the Treated set who had a baseline HbA1c assessment and at least 1 on-treatment HbA1c assessment during the double-blind part of the trial.
| Percentage of HbA1c | Lina5 (E10) | Plc (E10) | Lina5 (E25) | Plc (E25) |
|---|---|---|---|---|
| Change From Baseline of HbA1c After 24 Weeks of Treatment. | -0.53 ± 0.07 | -0.21 ± 0.07 | -0.58 ± 0.07 | -0.10 ± 0.07 |
Change from baseline FPG (mmol/L) after 24 weeks of treatment with double-blind trial medication, i.e. FPG change from baseline at Week 24.
| mmol/L | Lina5 (E10) | Plc (E10) | Lina5 (E25) | Plc (E25) |
|---|---|---|---|---|
| Fasting Plasma Glucose (FPG) Change From Baseline at 24 Weeks. | -0.44 ± 0.18 | 0.21 ± 0.18 | -0.68 ± 0.15 | -0.24 ± 0.15 |
Collected over From first drug administration until 7 days after the last drug administration, up to 212 days (OL treatment period) and 205 days (double blind treatment period).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Empa 10 mg OL | — | 12/352 (3.4%) | 47/352 (13.4%) |
| Empa 25 mg OL | — | 12/354 (3.4%) | 38/354 (10.7%) |
| Lina5 (E10) | — | 4/126 (3.2%) | 22/126 (17.5%) |
| Plc (E10) | — | 5/128 (3.9%) | 10/128 (7.8%) |
| Lina5 (E25) | — | 3/112 (2.7%) | 18/112 (16.1%) |
| Plc (E25) | — | 4/112 (3.6%) | 21/112 (18.8%) |
| Event | Empa 10 mg OL | Empa 25 mg OL | Lina5 (E10) | Plc (E10) | Lina5 (E25) | Plc (E25) |
|---|---|---|---|---|---|---|
| OsteomyelitisInfections and infestations | 0/352 | 0/354 | 0/126 | 0/128 | 0/112 | 2/112 |
| Atrial flutterCardiac disorders | 0/352 | 0/354 | 0/126 | 0/128 | 1/112 | 0/112 |
| TachycardiaCardiac disorders | 0/352 | 0/354 | 0/126 | 0/128 | 1/112 | 0/112 |
| Intestinal polypGastrointestinal disorders | 0/352 | 0/354 | 0/126 | 0/128 | 0/112 | 1/112 |
| FallInjury, poisoning and procedural complications | 1/352 | 0/354 | 0/126 | 0/128 | 0/112 | 1/112 |
| HaemarthrosisMusculoskeletal and connective tissue disorders | 0/352 | 0/354 | 0/126 | 0/128 | 0/112 | 1/112 |
| Pharyngeal lesionRespiratory, thoracic and mediastinal disorders | 0/352 | 0/354 | 0/126 | 0/128 | 1/112 | 0/112 |
| Dermatitis bullousSkin and subcutaneous tissue disorders | 0/352 | 0/354 | 0/126 | 0/128 | 1/112 | 0/112 |
| Dyshidrotic eczemaSkin and subcutaneous tissue disorders | 0/352 | 0/354 | 0/126 | 0/128 | 1/112 | 0/112 |
| Extremity necrosisVascular disorders | 0/352 | 0/354 | 0/126 | 0/128 | 0/112 | 1/112 |
| Event | Empa 10 mg OL | Empa 25 mg OL | Lina5 (E10) | Plc (E10) | Lina5 (E25) | Plc (E25) |
|---|---|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 16/352 | 23/354 | 10/126 | 6/128 | 11/112 | 7/112 |
| NasopharyngitisInfections and infestations | 17/352 | 5/354 | 8/126 | 3/128 | 2/112 | 8/112 |
| Lipase increasedInvestigations | 15/352 | 10/354 | 4/126 | 1/128 | 7/112 | 7/112 |
The open-label treated set (OLTS) was used for the open label treatment period. This analysis set consisted of all patients who received at least 1 dose of open-label treatment during the trial.
| Age, Continuous(Years) | Empa 10 mg OL | Empa 25 mg OL | Total |
|---|---|---|---|
| Mean | 57.0 ± 9.6 | 56.7 ± 9.9 | 56.8 ± 9.8 |
| Sex: Female, Male(Participants) | Empa 10 mg OL | Empa 25 mg OL | Total |
|---|---|---|---|
| Female | 145 | 161 | 306 |
| Male | 207 | 193 | 400 |
Showing the first 100 of 114 sites across 11 countries. Choose a country and city above to see the rest.
The record gives a start of Jan 2013, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Empagliflozin · Linagliptin